Merck KGaA (FRA:MRK) Receives Consensus Rating of “Hold” from Brokerages

Shares of Merck KGaA (FRA:MRK) have been given an average rating of “Hold” by the nineteen analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is €100.67 ($117.05).

Several brokerages have recently issued reports on MRK. Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the stock a “neutral” rating in a report on Friday, August 9th. Barclays set a €82.00 ($95.35) target price on Merck KGaA and gave the stock a “sell” rating in a report on Wednesday, August 14th. Deutsche Bank set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a “neutral” rating in a report on Friday, August 9th. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the stock a “neutral” rating in a report on Friday, August 9th. Finally, HSBC set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a “neutral” rating in a report on Thursday, August 15th.

Shares of MRK stock traded down €0.32 ($0.37) during trading hours on Friday, hitting €94.90 ($110.35). The stock had a trading volume of 305,353 shares. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72). The stock’s 50-day moving average price is €93.93 and its two-hundred day moving average price is €94.61.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: Google Finance Portfolio Tips and Tricks

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.